Tell us about your search experience on the TGA website - complete our short survey
TGA grants provisional determination for the Moderna bivalent COVID-19 vaccine "SPIKEVAX Bivalent Zero/Omicron"
On 27 April 2022 the TGA granted a provisional determination to Moderna Australia Pty Ltd in relation to its bivalent COVID-19 vaccine, elasomeran/elasomeran 0-omicron (SPIKEVAX Bivalent Zero/Omicron).
Published
Related content
- TGA grants provisional determinations to Pfizer for COVID-19 vaccines to target Omicron variantOn 5 July 2022 the TGA granted two provisional determinations to Pfizer Australia Pty Ltd.
- TGA grants provisional determination to Moderna’s COVID-19 bivalent (Original plus Omicron BA.4/BA.5) booster dose vaccineThe TGA has granted a provisional determination to Moderna Australia Pty Ltd’s bivalent COVID-19 vaccine candidate: elasomeran and davesomeran (SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4/BA.5)
- Provisional determination granted to Pfizer in relation to COVID 19 vaccine, COMIRNATY - for use in individuals 6 months up to 5 yearsOn 28 June 2022 the TGA granted a provisional determination to Pfizer Australia Pty Ltd in relation to its COVID-19 Vaccine, COMIRNATY.